A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

ABSTRACT:

Context

Prediction of high probability of survival from standard cancer treatments is fundamental for individualized cancer treatment strategies.

Objective

To develop a predictor of response and survival from chemotherapy for newly diagnosed invasive breast cancer.

Design, setting, and patients

Prospective multicenter study conducted from June 2000 to March 2010 at the M. D. Anderson Cancer Center to develop and test genomic predictors for neoadjuvant chemotherapy. Patients were those with newly diagnosed ERBB2 (HER2 or HER2/neu)-negative breast cancer treated with chemotherapy containing sequential taxane and anthracycline-based regimens (then endocrine therapy if estrogen receptor [ER]-positive). Different predictive signatures for resistance and response to preoper

SUBMITTER: Hatzis C 

PROVIDER: S-EPMC5638042 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature